FDB to Present Poster on Knowledge Management of Drug Information for Antibiotic Stewardship at AMIA Conference
Research-based prototype model of antibiotic drug information provides clinical decision support to promote antibiotic stewardship
South San Francisco, CA
11/2/2018 10:48:00 AM
FDB (First Databank, Inc.), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, today announced that it will present a poster by a team of FDB pharmacists at the AMIA 2018 Annual Symposium, November 3-7, 2018, in San Francisco. Christine M. Cheng, PharmD and Jeff Bubp, PharmD, will present the poster and answer related questions on November 5 from 5:00 to 6:30 pm in the Grand Ballroom, Hilton San Francisco Union Square.
The poster summarizes existing efforts to address antibiotic resistance, a well-recognized major public health concern, and proposes a data model for antibiotic stewardship (ABS) that can be integrated within the electronic health record and used within the electronic workflow to support antibiotic prescribing, surveillance and reporting.
Christine M. Cheng, PharmD and Jeff Bubp, PharmD, authors of the poster, “Knowledge Management of Drug Information for Antibiotic Stewardship,” developed a prototype data model of antibiotic drug information to support different ABS use cases, including evidence-based prescribing (empiric and definitive), regimen optimization, intravenous-to-oral (IV-to-PO) switch, and antimicrobial surveillance and reporting. The model includes data elements such as site and source of infection, patient factors, organism characteristics, and evidence-based antibiotic regimens for empiric and definitive therapy. Elements can be tailored to the specific need of the clinician or institution and, where possible, link to existing knowledge content and standard terminologies.
"With our extensive drug database, we are in a unique position to lead the industry in collaborating to create a new resource to reduce inappropriate antibiotic use,” said Christine M. Cheng, PharmD, FDB. “Our model may be the first to propose a single knowledge base and integrated application that proactively uses both patient and discrete microbiology results to support evidence-based antibiotic choice within the electronic workflow.”
Clinical and drug pricing information from FDB is utilized by thousands of hospitals, payers and pharmacies across the United States, as well as by the majority of state Medicaid agencies, CMS, the Department of Defense, and the Veterans Administration.
About First Databank (FDB)
FDB is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver valuable, useful, and differentiated solutions. We offer more than three decades of experience in transforming medical knowledge into actionable, targeted, and effective solutions that help improve patient safety, operational efficiency, and healthcare outcomes. For a complete look at our solutions and services, please visit www.fdbhealth.com or follow us on Twitter and LinkedIn.
About Hearst Health
The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health Ventures and the Hearst Health Innovation Lab (www.hearsthealth.com). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 70 million home health visits and 3.2 billion dispensed prescriptions.
First Databank (FDB)
©2018 First Databank, Inc. Part of the Hearst Health network. All trademarks mentioned herein are the properties of their respective owners.